Marinus Pharma (MRNS) Misses Q3 EPS by 1c, narrows product revenue guidance

Marinus Pharma (NASDAQ: MRNS) reported Q3 EPS of ($0.42), $0.01 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $8.54 million versus the consensus estimate of $9.42 million.

Narrowing full year 2024 ZTALMY net product revenue guidance to $33 to $34 million

For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• SeaStar Medical (ICU) Misses Q1 EPS by 4c
• CAE, Inc. (CAE) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY27 EPS Guidance